A case-control study involving 98 UC patients and 105 CD patients revealed the involvement of immune-mediated interleukin (IL)-22 in the development of IBD (6). A prospective study revealed that α-2 macroglobulin (LRG), interleukin (IL)-6, prealbumin (pre-Alb), high-sensitivity CRP (hs-CRP), CRP, and fecal calprotectin (FC) are associated with changes in UC disease activity, with LRG also reflecting disease activity during anti-tumor necrosis factor (TNF) antibody treatment (7). This evidence concerns the gene IL6 and inflammatory bowel disease.